40. Doggrell SA (2004) The potential of activation of somatostatinergic neurotrans- mission with FK960 in Alzheimer’s disease. Expert Opin Investig Drugs 13: 69–72. 41. Fox L, Alford M, Achim C, Mallory M, Masliah E (1997) Neurodegeneration of somatostatin-immunoreactive neurons in HIV encephalitis. J Neuropathol Exp Neurol 56: 360–368. 42. Kumar U (2005) Expression of somatostatin receptor subtypes (SSTR1-5) in Alzheimer’s disease brain: An immunohistochemical analysis. Neuroscience 134: 525–538. 43. Bibb JA, Yan Z, Svenningsson P, Snyder GL, Pieribone VA, et al. (2000) Severe deficiencies in dopamine signaling in presymptomatic Huntington’s disease mice. Proc Natl Acad Sci U S A 97: 6809–6814. 44. Torres-Peraza J, Pezzi S, Canals JM, Gavalda N, Garcia-Martinez JM, et al. (2007) Mice heterozygous for neurotrophin-3 display enhanced vulnerability to excitotoxicity in the striatum through increased expression of N-methyl-D- aspartate receptors. Neuroscience 144: 462–471. 45. Rajput PS, Billova S, Patel SC, Kharmate G, Somvanshi RK, et al. (2009) Expression of somatostatin and somatostatin receptor subtypes in Apolipopro- tein D (ApoD) knockout mouse brain: An immunohistochemical analysis. J Chem Neuroanat 38: 20–33. 46. Ramirez JL, Grant M, Norman M, Wang XP, Moldovan S, et al. (2004) Deficiency of somatostatin (SST) receptor type 5 (SSTR5) is associated with sexually dimorphic changes in the expression of SST and SST receptors in brain and pancreas. Mol Cell Endocrinol 221: 105–119. 47. Hernandez-Espinosa D, Morton AJ (2006) Calcineurin inhibitors cause an acceleration of the neurological phenotype in a mouse transgenic for the human Huntington’s disease mutation. Brain Res Bull 69: 669–679. 48. Cowan CM, Fan MM, Fan J, Shehadeh J, Zhang LY, et al. (2008) Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity. J Neurosci 28: 12725–12735. 49. Fernandes HB, Baimbridge KG, Church J, Hayden MR, Raymond LA (2007) Mitochondrial sensitivity and altered calcium handling underlie enhanced NMDA-induced apoptosis in YAC128 model of Huntington’s disease. J Neurosci 27: 13614–13623. 50. Helyes Z, Pinter E, Sandor K, Elekes K, Banvolgyi A, et al. (2009) Impaired defense mechanism against inflammation, hyperalgesia, and airway hyperreac- tivity in somatostatin 4 receptor gene-deleted mice. Proc Natl Acad Sci U S A 106: 13088–13093. 51. Viollet C, Vaillend C, Videau C, Bluet-Pajot MT, Ungerer A, et al. (2000) Involvement of sst2 somatostatin receptor in locomotor, exploratory activity and emotional reactivity in mice. Eur J Neurosci 12: 3761–3770. 52. Greengard P, Allen PB, Nairn AC (1999) Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron 23: 435–447. 53. Svenningsson P, Lindskog M, Ledent C, Parmentier M, Greengard P, et al. (2000) Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2, and adenosine A2A receptors. Proc Natl Acad Sci U S A 97: 1856–1860. 54. Baragli A, Alturaihi H, Watt HL, Abdallah A, Kumar U (2007) Hetero- oligomerization of human dopamine receptor 2 and somatostatin receptor 2 Co- immunoprecipitation and fluorescence resonance energy transfer analysis. Cell Signal 19: 2304–2316. 55. Rajput PS, Kharmate G, Somvanshi RK, Kumar U (2009) Colocalization of dopamine receptor subtypes with dopamine and cAMP-regulated phosphopro- tein (DARPP-32) in rat brain. Neurosci Res 65: 53–63. 56. Gladding CM, Raymond LA (2011) Mechanisms underlying NMDA receptor synaptic/extrasynaptic distribution and function. Mol Cell Neurosci. Somatostatin Receptor 1/5 Knockout and R6/2 Mice 57. Hardingham GE (2009) Coupling of the NMDA receptor to neuroprotective and neurodestructive events. Biochem Soc Trans 37: 1147–1160. 58. Hardingham GE, Bading H (2010) Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci 11: 682–696. 59. Ali NJ, Levine MS (2006) Changes in expression of N-methyl-D-aspartate receptor subunits occur early in the R6/2 mouse model of Huntington’s disease. Dev Neurosci 28: 230–238. 60. Cepeda C, Ariano MA, Calvert CR, Flores-Hernandez J, Chandler SH, et al. (2001) NMDA receptor function in mouse models of Huntington disease. J Neurosci Res 66: 525–539. 61. Milnerwood AJ, Raymond LA (2010) Early synaptic pathophysiology in neurodegeneration: insights from Huntington’s disease. Trends Neurosci 33: 513–523. 62. Grant M, Kumar U (2010) The role of G-proteins in the dimerisation of human somatostatin receptor types 2 and 5. Regul Pept 159: 3–8. 63. Miyakawa T, Leiter LM, Gerber DJ, Gainetdinov RR, Sotnikova TD, et al. (2003) Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. Proc Natl Acad Sci U S A 100: 8987–8992. 64. Blank T, Nijholt I, Teichert U, Kugler H, Behrsing H, et al. (1997) The phosphoprotein DARPP-32 mediates cAMP-dependent potentiation of striatal N-methyl-D-aspartate responses. Proc Natl Acad Sci U S A 94: 14859–14864. 65. Bastia E, Schwarzschild MA (2003) DARPP chocolate: a caffeinated morsel of striatal signaling. Sci STKE 2003: PE2. 66. Gafni J, Ellerby LM (2002) Calpain activation in Huntington’s disease. J Neurosci 22: 4842–4849. 67. Gafni J, Hermel E, Young JE, Wellington CL, Hayden MR, et al. (2004) Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus. J Biol Chem 279: 20211–20220. 68. Menalled L, Zanjani H, MacKenzie L, Koppel A, Carpenter E, et al. (2000) Decrease in striatal enkephalin mRNA in mouse models of Huntington’s disease. Exp Neurol 162: 328–342. 69. Sun Z, Del Mar N, Meade C, Goldowitz D, Reiner A (2002) Differential changes in striatal projection neurons in R6/2 transgenic mice for Huntington’s disease. Neurobiol Dis 11: 369–385. 70. Lione LA, Carter RJ, Hunt MJ, Bates GP, Morton AJ, et al. (1999) Selective discrimination learning impairments in mice expressing the human Huntington’s disease mutation. J Neurosci 19: 10428–10437. 71. Tallent M, Liapakis G, O’Carroll AM, Lolait SJ, Dichter M, et al. (1996) Somatostatin receptor subtypes SSTR2 and SSTR5 couple negatively to an L- type Ca2+ current in the pituitary cell line AtT-20. Neuroscience 71: 1073–1081. 72. Somvanshi RK, Billova S, Kharmate G, Rajput PS, Kumar U (2009) C-tail mediated modulation of somatostatin receptor type-4 homo- and heterodimer- izations and signaling. Cell Signal 21: 1396–1414. 73. Kumar U (2007) Colocalization of somatostatin receptor subtypes (SSTR1-5) with somatostatin, NADPH-diaphorase (NADPH-d), and tyrosine hydroxylase in the rat hypothalamus. J Comp Neurol 504: 185–205. 74. Wang XP, Norman MA, Yang J, Cheung A, Moldovan S, et al. (2004) Double- gene ablation of SSTR1 and SSTR5 results in hyperinsulinemia and improved glucose tolerance in mice. Surgery 136: 585–592. 75. Billova S, Galanopoulou AS, Seidah NG, Qiu X, Kumar U (2007) Immunohistochemical expression and colocalization of somatostatin, carboxy- peptidase-E and prohormone convertases 1 and 2 in rat brain. Neuroscience 147: 403–418. PLoS ONE | www.plosone.org 12 September 2011 | Volume 6 | Issue 9 | e24467